 CHERRY HILL, N.J., Aug. 19, 2022 GLOBE NEWSWIRE -- Vyant Bio, Inc. Vyant Bio or Company Nasdaq: VYNT is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Companys proprietary central nervous system CNS drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 22, 2022. Vyant Bio will host an investor conference call and webcast on Monday, August 22, 2022 at 4:30 pm ET. 